Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
6.52
+0.16 (2.52%)
Jun 26, 2026, 3:17 PM EDT - Market open
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$44,293
Profits / Employee
-$2,090,187
Market Cap
354.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| Verastem | 102 |
| OmniAb | 89 |
| Silence Therapeutics | 88 |
| Atea Pharmaceuticals | 55 |
| DiaMedica Therapeutics | 35 |
| Fennec Pharmaceuticals | 35 |
UPB News
- 8 days ago - Upstream Bio management to meet with Piper Sandler - TheFly
- 11 days ago - Upstream Bio presents new responder analyses from VIBRANT trial of verekitug - TheFly
- 12 days ago - Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 - GlobeNewsWire
- 13 days ago - KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust - Business Wire
- 14 days ago - Upstream Bio downgraded to Neutral from Overweight at JPMorgan - TheFly
- 16 days ago - Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Upstream Bio Transcript: AGM 2026 - Transcripts
- 18 days ago - Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - GlobeNewsWire